N,6-dimethylbenzo[d]isoxazol-3-amine | 1378801-83-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并异恶唑
• 英文名称: N,6-dimethylbenzo[d]isoxazol-3-amine
• 英文别名: N,6-dimethyl-1,2-benzoxazol-3-amine
• CAS: 1378801-83-2
• 化学式: C₉H₁₀N₂O
• 分子量: 162.191
• InChiKey: OQRMFDGOGUWOSC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  38.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  7-iodo-N,6-dimethylbenzo[d]isoxazol-3-amine 、 频那醇硼烷 在 palladium diacetate 、 三乙胺 、 2-二环己基磷-2'-甲基联苯 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 0.33h， 生成 N,6-dimethylbenzo[d]isoxazol-3-amine 、 N,6-dimethyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxoborolan-2-yl)benzo[d]isoxazol-3-amine
  参考文献：
  名称：

  Discovery and Evaluation of 7-Alkyl-1,5-bis-aryl-pyrazolopyridinones as Highly Potent, Selective, and Orally Efficacious Inhibitors of p38α Mitogen-Activated Protein Kinase^⊥⊥ Atomic coordinates and structure factors for crystal structure of compound3dwith p38α can be accessed using PDB code 3LHJ.

  摘要：

  The p38 alpha mitogen-activated protein (MAP) kinase is a central signaling molecule in many proinflammatory pathways, regulating the cellular response to a multitude of external stimuli including heat, ultraviolet radiation, osmotic shock, and a variety of cytokines especially interleukin-1 beta and tumor necrosis factor alpha. Thus, inhibitors of this enzyme are postulated to have significant therapeutic potential for the treatment of rheumatoid arthritis, inflammatory bowel disease, and Crohn's disease, as well as other diseases where aberrant cytokine signaling is the driver of disease. In this communication, we describe a novel class of 7-alkyl-1,5-bis-aryl-pyrazolopyridinone-based p38 alpha inhibitors. In particular, compound 3f is highly potent in the enzyme and cell-based assays, selective in an Ambit kinase screen, and efficacious (ED50 <= 0.01 mg/kg) in the rat collagen induced arthritis (CIA) model.

  DOI：

  10.1021/jm100095x

文献信息

• TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
  申请人：Shanghai Jemincare Pharmaceuticals Co., Ltd.

  公开号：EP3998263A1

  公开（公告）日：2022-05-18

  A compound represented by formula (I), an optical isomer thereof and a pharmaceutically acceptable salt thereof, as well as an application of said compound as an FXIa inhibitor.

  化合物(I)及其光学异构体和药学上可接受的盐，以及该化合物作为FXIa抑制剂的应用。
• Tricyclic compound, preparation method therefor and use thereof
  申请人：SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD.

  公开号：US11518766B2

  公开（公告）日：2022-12-06

  A compound represented by formula (I), an optical isomer thereof and a pharmaceutically acceptable salt thereof, as well as an application of said compound as an FXIa inhibitor.

  一种由式（I）代表的化合物、其光学异构体和其药学上可接受的盐，以及所述化合物作为 FXIa 抑制剂的应用。
• MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS
  申请人：Mochida Pharmaceutical Co., Ltd.

  公开号：EP2473491B1

  公开（公告）日：2013-07-17
• Discovery and Evaluation of 7-Alkyl-1,5-bis-aryl-pyrazolopyridinones as Highly Potent, Selective, and Orally Efficacious Inhibitors of p38α Mitogen-Activated Protein Kinase^⊥⊥ Atomic coordinates and structure factors for crystal structure of compound<b>3d</b>with p38α can be accessed using PDB code 3LHJ.
  作者：Liping H. Pettus、Ryan P. Wurz、Shimin Xu、Brad Herberich、Bradley Henkle、Qiurong Liu、Helen J. McBride、Sharon Mu、Matthew H. Plant、Christiaan J. M. Saris、Lisa Sherman、Lu Min Wong、Samer Chmait、Matthew R. Lee、Christopher Mohr、Faye Hsieh、Andrew S. Tasker

  DOI：10.1021/jm100095x

  日期：2010.4.8

  The p38 alpha mitogen-activated protein (MAP) kinase is a central signaling molecule in many proinflammatory pathways, regulating the cellular response to a multitude of external stimuli including heat, ultraviolet radiation, osmotic shock, and a variety of cytokines especially interleukin-1 beta and tumor necrosis factor alpha. Thus, inhibitors of this enzyme are postulated to have significant therapeutic potential for the treatment of rheumatoid arthritis, inflammatory bowel disease, and Crohn's disease, as well as other diseases where aberrant cytokine signaling is the driver of disease. In this communication, we describe a novel class of 7-alkyl-1,5-bis-aryl-pyrazolopyridinone-based p38 alpha inhibitors. In particular, compound 3f is highly potent in the enzyme and cell-based assays, selective in an Ambit kinase screen, and efficacious (ED50 <= 0.01 mg/kg) in the rat collagen induced arthritis (CIA) model.